Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases by Caputo, Sandrine et al.
Description and analysis of genetic variants in
French hereditary breast and ovarian cancer
families recorded in the UMD-BRCA1/BRCA2
databases
Sandrine Caputo
1,*, Louisa Benboudjema
1, Olga Sinilnikova
2,3, Etienne Rouleau
1,
Christophe Be ´roud
4,5,6, Rosette Lidereau
1 and the French BRCA GGC Consortium
y
1Institut Curie—Ho ˆpital Rene ´ Huguenin, Service d’Oncoge ´ne ´tique, U735 INSERM—Saint-Cloud,
2Unite ´ Mixte de Ge ´ne ´tique Constitutionnelle des Cancers Fre ´quents, Hospices Civils de Lyon—Centre Le ´on
Be ´rard, Lyon,
3INSERM U1052, CNRS UMR5286, Universite ´ Lyon 1, Centrede Recherche en Cance ´rologie de
Lyon, Lyon,
4INSERM U827—Montpellier,
5CHU Montpellier, Ho ˆpital Arnaud de Villeneuve, Laboratoire de
Ge ´ne ´tique Mole ´culaire—Montpellier and
6Universite ´ Montpellier1, UFR Me ´decine—Montpellier, F-34000, France
Received August 15, 2011; Revised October 15, 2011; Accepted November 10, 2011
ABSTRACT
BRCA1 and BRCA2 are the two main genes respon-
sible for predisposition to breast and ovarian
cancers, as a result of protein-inactivating mono-
allelic mutations. It remains to be established
whether many of the variants identified in
these two genes, so-called unclassified/unknown
variants (UVs), contribute to the disease phenotype
or are simply neutral variants (or polymorphisms).
Given the clinical importance of establishing their
status, a nationwide effort to annotate these UVs
was launched by laboratories belonging to the
French GGC consortium (Groupe Ge ´ne ´tique et
Cancer), leading to the creation of the
UMD-BRCA1/BRCA2 databases (http://www.umd
.be/BRCA1/ and http://www.umd.be/BRCA2/).
These databases have been endorsed by the
French National Cancer Institute (INCa) and are
designed to collect all variants detected in France,
whether causal, neutral or UV. They differ from other
BRCA databases in that they contain co-occurrence
data for all variants. Using these data, the GGC
French consortium has been able to classify
certain UVs also contained in other databases. In
this article, we report some novel UVs not contained
in the BIC database and explore their impact in
cancer predisposition based on a structural
approach.
INTRODUCTION
BRCA1 and BRCA2 are the two main genes predisposing
individuals to breast and/or ovarian cancer. Most
monoallelic germline mutations in these genes are point
variants or deletions/insertions of a few nucleotides. Large
rearrangements (exon loss or duplication, 50 alterations,
etc...) have also been described (1,2). These mutations
are situated throughout the entire sequence of the two
genes. In France, causal mutations in BRCA1 and
BRCA2 genes account for about 15% of hereditary
breast and ovarian cancers (HBOC) (3).
The pathogenic nature of variants resulting in a prema-
ture termination codon (PTC) has been clearly established
for those variants leading to nonsense-mediated decay
(NMD) (4–7), i.e. BRCA1 proteins with a PTC located
upstream from the last 10 carboxy-terminal codons, and
BRCA2 proteins with a PTC located upstream from
the last 110 carboxy-terminal codons. Some speciﬁc
missense variants can generate a PTC via abnormal
splicing, while others clearly alter the function of
BRCA1, including all those occurring in the RING
ﬁnger and some located in BRCT domains (8). The patho-
genicity of these variants has been inferred from linkage
analysis of high-risk families, functional assays, biochem-
ical studies and/or demonstration of abnormal mRNA
processing (8–10).
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of breast and ovarian cancer predisposition relates to the
large number of variants with unclear clinical signiﬁcance.
Variants that do not create a PTC represent a signiﬁcant
proportion of DNA variants and are usually called unclas-
siﬁed variants (UVs). UVs mostly consist of missense and
intronic variants and in-frame deletions or insertions.
Exhaustive collections of UVs could allow cosegregation
studies within pedigrees, and these complementary data
could help to deﬁne a reliable classiﬁcation. Whether a
given UV contributes to the disease phenotype or is
merely a neutral variant (or a neutral polymorphism)
has direct clinical implications.
Several approaches can be used to determine pathogen-
icity, including multidisciplinary analysis of cosegregation
within pedigrees and degree of family history of the
disease, or by indirect measures, including amino acid
conservation, severity of amino acid change and
evidence from functional assays, outputs from available
bioinformatics tools, tumor pathology (11,12), population
genetics and comparisons of allele frequencies (13), lack of
co-occurrence with causal mutations (14), RNA and
protein function studies (15), evolutionary studies of
amino acid conservation (16) and a recently proposed
combinatorial approach (17). However, such approaches
cannot deﬁnitively show whether or not a speciﬁc variant
is causal.
Mutation databases can help to classify variants by
providing a unique source of information. The Breast
Cancer Information Core Database (http://research
.nhgri.nih.gov/projects/bic/index.shtml: BIC) is a volun-
tary international collection of variants identiﬁed world-
wide (18). Other online databases include LOVD (Leiden
Open Variation Database)-literature unclassiﬁed variant
(http://chromium.liacs.nl/LOVD2/cancer/home.php) (19),
LOVD-IARC (http://brca.iarc.fr/LOVD/home.php),
kConFab (Kathleen Cuningham Foundation
Consortium for Research into Familial Breast Cancer)
(20), The Singapore Human Mutation and
Polymorphism Database (21), and HGMD (The Human
Gene Mutation Database at the Institute of Medical
Genetics in Cardiff) (22), NGRL/DmuDb (https://ngrl
.manchester.ac.uk/Browser/genes.htm).
In this report, we present exhaustive databases of
French BRCA1/2 variants (UMD-BRCA1/BRCA2:
http://www.umd.be/BRCA1/ and http://www.umd.be/
BRCA2/) developed with UMD software (23). These
databases have been endorsed by the French Cancer
National Institute (INCa) and are available online. A
curator collects and compiles information from 16
licensed laboratories belonging to the French GGC con-
sortium (Groupe Ge ´ ne ´ tique et Cancer) and located all
over France. UMD-BRCA1/BRCA2 databases centralize
all variants (causal, neutral and UVs), allowing identiﬁca-
tion of co-occurrence data. Data on polymorphisms were
not collected. In October 2011, the UMD-BRCA1/
BRCA2 databases contained data from a set of 3743
families for BRCA1 and 3,650 families for BRCA2.I n
this report, we ﬁrst analyze BRCA1/BRCA2 variants in
the French population, and then use our co-occurrence
data to classify some UVs as either causal or neutral.
Finally, we describe BRCA1 and BRCA2 UVs and
evaluate their pathogenicity, notably from a structural
standpoint (Supplementary Data). Therefore, this
database should be a tool to classify variant and
promote speciﬁc studies.
MATERIALS AND METHODS
Software and search engine
The UMD-BRCA1/BRCA2 databases were constructed
with an updated version of the Universal Mutation
Database generic software (http://www.umd.be) (23,24),
which includes an optimized structure to assist and
secure data entry and to allow the input of various
clinical or biological data. An ofﬂine copy of
UMD-BRCA1/BRCA2 is continuously edited and
updated by the curators; edited copies are regularly de-
posited on the server. These databases are freely available
online. Their integrity is ensured by the original (edited)
template ofﬂine. Notiﬁcation of errors in the current
version would be gratefully received by the curator
author. Database design follows general recommenda-
tions for LSDB characteristics and their curation as
proposed by the Human Genome Variation Society
(HGVS) (25).
Website
The Website is divided into six sections, four of which are
dedicated to information on the BRCA1 or BRCA2 genes
and numbering of exons and cDNA sequences, informa-
tion on the protein and the references, while two sections
allow the user to search into the database. Hyperlinks are
provided to access the reference sequences and data search
capabilities. The web pages also contain links to external
information including central biological databases, such
the Human Genome Database (GDB), Pubmed,
GeneCard, UniGene, Uniprot, OMIM, HGV, etc.
Probands
About 24000 probands were managed at the medical
genetics departments of French Comprehensive Cancer
Care centers and hospitals between January 1995 and
October 2011. Eligibility criteria for familial genetic
testing are described in the French consensus statement
(26). All probands enrolled in this study gave their
written informed consent for speciﬁc genetic testing. The
probands were the index cases of individual families and
were screened for BRCA1 and BRCA2 variants. Records
in the French UMD-BRCA1/BRCA2 databases are
restricted to index cases of families with clearly causal
mutations, neutral variants or UVs. A system of ﬁve
classes has been used for classiﬁcation (27). An
anonymized and unique sample identiﬁer (sample_ID) is
generated for each family.
Variant screening
The full coding sequences and exon–intron junctions
of the BRCA1 and BRCA2 genes were screened for
variants, based on prescreening (DGGE, SSCP, PTA,
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rearrangements were identiﬁed by large cDNA
sequencing, MLPA (28), QMPSF (29), qPCR (30),
qPCR HRM (31), EMMA (32), bar code screening (33)
or dedicated array CGH (34).
UMD-BRCA1/BRCA2 databases
The UMD software includes an automatic procedure to
check for the correct description of the sequence variation
at the nucleotide level and to generate the variant name
at the protein level. All variant types are documented.
All variants were subjected to a curation process and
named according to the HGVS nomenclature before inte-
gration in the databases. Variants previously described
either in publications or in other BRCA1/2 databases
were reviewed. Data on 7396 different BRCA1/BRCA2
families were collected between 1995 and October 2011
(Table 2). Co-occurrence of each UV with causal muta-
tions was recorded in the databases. Data on polymorph-
ism were not collected. Families were recorded only once,
independently of the number of members tested. No
clinical data were collected.
The present version of BRCA1 and BRCA2 is based on
GenBank reference sequences NM_007294.2 (mRNA:
U14680) and NM_000059.3 (mRNA: U43746), respect-
ively. For BRCA1, this entry includes 119 bases of
50-untranslated sequence with protein translation starting
at nucleotide 120. The reference BRCA2 sequence also
includes the 228-base 50-untranslated region.
Searching tools
The UMD knowledgebase system includes many analyt-
ical tools (23,24). In addition to previously developed
routines, new tools have been speciﬁcally developed for
the UMD-BRCA1/BRCA2 for in-depth analysis. The
user is able to optimize multicriteria search tools to
select records from any ﬁeld.
Prequeried data can be displayed by several Searching
Tools in ‘Mutations’ such as ‘Type and number of muta-
tions’ or ‘Mutation by exon/intron’ (Supplementary
Figure S1A). Alternatively, the option ‘I found a
mutation’ provides access to a quick search (nucleotide
or amino acid position), ‘Free search’ provides access to
an advanced search and a customized search interface
searching several items (sample ID, amino acid position,
biological signiﬁcance, etc). A simple click on hyperlinks
provides access to a list of interesting variants
(Supplementary Data).
Variant analysis
For co-occurrence analysis, a UV in trans with two differ-
ent causal mutations, was considered to be unlikely to
cause disease.
The impact of missense substitutions in the BRCA1/2
genes was predicted by using three online programs:
Align-GVGD (35), SIFT (36) and PolyPhen (37), which
predict the effect of missense substitutions on gene
function, as well as the new UMD-Predictor tool
included in the UMD package (17).
For structural analysis, we focused on some novel
variants not contained in the BIC database and located
in a conserved region or in a previously reported function-
al domain. Regions and domains of BRCA1 or BRCA2
are described in Supplementary Data (Supplementary
Figure S2).
RESULTS
UMD-BRCA1/BRCA2 databases
In UMD-BRCA1, a total of 1391 distinct BRCA1 variants
comprising 586 causal mutations (42%), 5 likely causal
mutations (0.4%), 22 likely neutral variants (1.6%), 74
neutral variants (5%) and 704 UVs (51%) have been
identiﬁed in 3743 French families (1 index case harbors
two different causal BRCA1 mutations and 81 cases
harbor one causal mutation associated with at least one
UV) (Tables 1 and 2). In UMD-BRCA2, a total of 1704
distinct BRCA2 variants were reported in 3650 families,
with 567 different causal mutations (33.1%), 17 likely
neutral variants (1%), 30 neutral variants (1.8%) and
1092 UVs (64.1%) (1 index case harbors two different
causal BRCA2 mutations and 129 cases harbor one
causal mutation and at least one UV) (Tables 1 and 2).
Three index cases were double heterozygotes for causal
BRCA1 and BRCA2 mutations. Most variants were
found in a unique family (517 of 704 BRCA1 UVs and
738 of 1092 BRCA2 UVs) (Table 1). A total of 3743
BRCA1 families (2636 causal mutations and 948 UVs)
and 3650 BRCA2 families (1576 causal mutations and
1775 UVs) were found to have at least one mutation
(Table 2).
The exon distribution of the UVs, neutral variants and
causal mutations in the UMD-BRCA1/BRCA2 databases
was also assessed and no statistically signiﬁcant differ-
ences were found between the UMD-BRCA1/BRCA2
and BIC databases (see Supplementary Data). Based on
the ratio between UMD-BRCA1/BRCA2 variants and
predicted variants, BRCA1 exons 2, 3, 5, 17, 18, 19 and
21 are the most frequently mutated exons (Supplementary
Table S1A). Exons 2, 3, and 5 correspond to the
RING-ﬁnger, exons 17, 18 and 19 to the ﬁrst BRCT
domain and exon 21 to the second BRCT. In BRCA2,
exons 2, 3, 18 and 23 are the most frequently mutated
exons (Supplementary Table S1B). Exon 18 correponds
to part of HD and OB1 domains and exon 23 correponds
to part of the OB2 domain. Structural data have been
previously available for only a small segment of exon 3
(residues 21–39), and no 3D structures have been
described or predicted for exon 2.
Characterization of French causal mutations in the
UMD-BRCA1/BRCA2 databases
The spectrum of causal mutations in the BRCA1 and
BRCA2 genes involves the entire sequence (Figure 1).
The BRCA1 exons most frequently mutated are exons 2,
5 and 20 and the BRCA2 exons most frequently mutated
are exons 8, 13 and 23 (Figure 1).
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in the French population were: the French founder frame-
shift c.3481_3491del (3600del11, exon 11) from North-
Eastern France (137 records) (38,39) and c.5266dup
(5382insC, exon 20), a founder Ashkenazi Jewish
mutation (138 records). This causal mutation was found
48 times in Ile-de-France and 27 times in North-Eastern
France. Six other frequent recurrent causal BRCA1 muta-
tions were observed more than 8 times (Table 3): all had
been recorded early in the BIC database (October 2011),
except for c.5128G>T (9 records), which was found 8 times
in North-Eastern France (39).
We identiﬁed eight frequent causal BRCA2 mutations
(Table 3), all of which were contained in the BIC
database (August 2011). The most prevalent causal
BRCA2 mutation in the French population is
c.2808_2811delACAA, a Western European mutation (41
records) (40). All of these eight recurrent causal BRCA2
mutations were frequently detected in the Paris region.
In comparison with the BIC database, the UMD
database also identiﬁed causal mutations from the
Ashkenazi Jewish population (26.88% for BIC-BRCA1
versus 6.14% UMD-BRCA1, 9.49% for BIC-BRCA2
versus 0.6% for UMD-BRCA2), but also several fre-
quent causal mutations from other European ethnic
populations.
Characterization of French UVs in the UMD-BRCA1/
BRCA2 databases
UVs were also detected throughout the two genes. The
most frequently mutated exons are 17, 18 and 19 for
BRCA1 and 15, 20 and 26 for BRCA2 (Figure 1).
As expected, numerous variants (at least 51% of distinct
variants in BRCA1 and 64.1% of distinct variants in
BRCA2) could not be classiﬁed as causal or neutral.
These UVs were found in BRCA1 in 1018 families and
in BRCA2 in 1944 families. In BRCA1, 704 distinct UVs
were identiﬁed in one or several families: 948 families with
one BRCA1 UV only, 81 with a UV associated with a
causal mutation and 70 with UVs only (Tables 1 and 2).
In BRCA2, 1092 distinct UVs were identiﬁed: 1775
families with one BRCA2 UV only, 129 with a UV
associated with a causal mutation and 169 with UVs
only (Tables 1 and 2).
Most UVs were observed only once (517/704 in BRCA1
and 738/1092 in BRCA2)( Table 1), while some were recur-
rent, including BRCA1 c.5075-53C>T (IVS17-53C>T,
SNP rs8176258) with 66 entries, c.5277+48_59dup
(IVS20+48_59dup, 47 entries) and BRCA2 c.7008-62A>G
(IVS13-62A>G, 69 entries), c.9257-16T>C (IVS24-16T>C,
SNP rs11571818, 50 entries) and c.6100C>T (p.Arg
2034Cys, exon 11, SNP rs1799954, 85 entries).
Table 2. Families and records distribution in the UMD-BRCA1/BRCA2 databases
Causal mutation UV
1 causal
mutation+x UV Total of families
BRCA1 5311 entries/3743 families
Families with 1 variation 2636 948 – 3584
Families with 2 variations 8 50 76 134
Families with 3 variations – 16 3 19
Families with 4 variations – 4 2 6
Total of families 2644 1018 81 3743
BRCA2 5532 entries/3650 families
Families with 1 variation 1576 1775 – 3351
Families with 2 variations 1 141 116 258
Families with 3 variations – 19 12 31
Families with 4 variations – 5 1 6
Families with 5 variations – 2 – 2
Families with 6 variations – 2 – 2
Total of families 1577 1944 129 3650
Causal mutations and UVs. There are three supplementary families with 1 causal BRCA1 mutation and 1 causal BRCA2 mutation.
Table 1. The October 2011 issue of UMD-BRCA1/BRCA2 databases
Causal Likely causal UV Likely neutral Neutral Total
BRCA1
Records 2733 (51.4%) 17 (0.3%) 1200 (22.6%) 190 (3.6%) 1171 (22.1%) 5311
Distinct variants 586 5 704 22 74 1391
Unique variants 311 1 517 5 9 843
BRCA2
Records 1707 (30.9%) – 2289 (41.4%) 387 (7%) 1149 (20.7%) 5532
Distinct variants 567 – 1092 17 30 1704
Unique variants 337 – 738 3 0 1078
Causal mutations, UVs and neutral
Nucleic Acids Research, 2012,Vol.40, Database issue D995Most UVs identiﬁed in this study were either missense
changes (45% in BRCA1 and 53.58% in BRCA2) or silent
variants (11.5% in BRCA1 and 15.38% in BRCA2)
(Figure 2). Small deletions or insertions of various
lengths were also observed (2.6% in BRCA1 and 2.19%
in BRCA2)( Figures 2), as well as intronic variants (40.9%
in BRCA1 and 15.38% in BRCA2)( Figure 2). Intronic
variants lie outside intron–exon boundaries and their
potential impact on the splicing process is difﬁcult to
predict and need speciﬁc RNA analysis (Figure 2).
GGC classiﬁcation of some UVs already reported in
other databases
Co-occurrence data on a UV in trans of a known causal
mutation (the UV and the causal mutation are on opposite
chromosomes) can provide a powerful means of ruling out
pathogenicity (14). Identiﬁcation of co-occurrence of a UV
and a causal mutation requires further investigations such
as cloning to exclude the in cis position of these two
variants (41). Without these additional analyses, there is
still a very weak probability that the two causal mutations
are situated in cis, which is why the following hypothesis
can be used: if a UV coexists with at least two different
causal mutations in two different families, this UV can be
considered to be always in trans with respect to the causal
mutation. To support the co-occurrence results, we also
used an integrated approach combining the Align-
GVGD, SIFT and PolyPhen programs, published data,
and the UMD-Predictor tool, allowing 3 BRCA2 UVs to
be classiﬁed as neutral and polymorphism (Table 4). These
BRCA2 UVs, described in the BIC database, were reported
in our databases as co-occurring with causal mutations:
c.6100C>T [p.Arg2034Cys, exon 11, 137 records, 16 in
trans (9 distinct causal mutations)], c.7008-62A>G
(IVS13-62A>G, 106 records, 6 distinct causal mutations
in trans), and c.9257-16T>C [IVS24-16T>C, 55 records, 8
in trans (4 distinct causal mutations)]. This suggests that
these variants do not sufﬁciently alter BRCA2 function to
predispose to cancer. The status of the BRCA2 c.6100C>T
variant differed between the algorithms: it was predicted
to be pathogenic by the UMD-Predictor tool and neutral
by SIFT, Align-GVGD, PolyPhen and co-occurrence
analysis. Moreover, c.6100C>T has been described as a
polymorphism in a Spanish population of cancer families
and patients (42). We classiﬁed this variant as a neutral
Figure 1. Distribution of all variants in the UMD-BRCA1/BRCA2 databases. The number of entries of all variants is represented per nucleotide
and per exon of BRCA1 or BRCA2.
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Nucleic Acids Research, 2012,Vol.40, Database issue D997variant. Our classiﬁcation is reported in the UMD-
BRCA1/BRCA2 databases. When it possible, a structral
approach is used to help classify the UVs (see example in
Supplementary Data: A structural approach to novel UVs).
DISCUSSION
The UMD-BRCA1/2 databases provide an overview
of the BRCA1/2 variants in the French population
We examined BRCA1/2 UVs collected by 16 licensed
laboratories located throughout France and belonging to
the French GGC consortium ‘Groupe Ge ´ ne ´ tique et
Cancer’, which is designed to validate diagnostic proced-
ures and strategies. The 16 licensed laboratories automat-
ically send all results of families tested in France with a
BRCA1/2 variant. Every 3 months, an update is per-
formed by all laboratories. The UMD-BRCA1/BRCA2
databases have been approved by the French National
Cancer Institute (INCa).
Among 24000 families tested, 2733 BRCA1 and 1707
BRCA2 families with one causal mutation were
identiﬁed, as well as 1018 BRCA1 and 1,944 BRCA2
families with at least one UV (Table 2). About 95% of
BRCA1/2 variants (causal mutations and UVs) were
observed only once.
Certain exons showed an excess of variants. Interest-
ingly, in BRCA1, these exons correspond to the RING-
ﬁnger domain and the ﬁrst BRCT domain, while in
BRCA2, the most frequently mutated exons are not
associated with resolved structural domains
(Supplementary Tables S1A and S1B).
Figure 2. Summary of all allelic variants contained in the UMD-BRCA1/2 mutation databases. Total number of types of variants in the BRCA1 and
BRCA2 genes.
D998 Nucleic AcidsResearch, 2012, Vol.40,Database issueAs in other populations, some variants are recurrent in
the French population (40,43–45). Sixteen recurrent causal
mutations in BRCA1 and BRCA2 were reported more
than eight times each. Some UVs were also recurrent.
Three were most frequent in BRCA2, namely c.7008-
62A>G (106 families), c.9257-16T>C (55 families) and
c.6100C>T (137 families). These three variants could be
geographic polymorphisms, or speciﬁc to the French
population. Detection of c.7008-62A>G and c.9257-
16T>C could also be variable according to the positions
of the primers used to amplify the region and the fre-
quency differs from one database to another due to the
selection of PCR primers.
The UMD-BRCA1/BRCA2 databases and pooled
data from the French GGC are sufﬁciently powerful
for co-occurrence studies. If homozygous and compound
heterozygous variants in BRCA1 are assumed to be
embryonically lethal (46–48), while those in BRCA2 are
responsible for Fanconi anemia (49–51), several variants
can be classiﬁed as neutral based on a single observation.
One patient reported in the UMD-BRCA1/BRCA2
databases harbors two different causal BRCA1 muta-
tions in cis (Bezieau, S. and Delnatte, C. unpublished
data). Another patient harbors two different causal
BRCA2 mutations. These two causal mutations result
in a breast/ovarian cancer syndrome but also in
glioblastoma (Sevenet, N., Longy, M. et al. unpublished
data).
A double heterozygote with a causal BRCA1 mutation
and a causal BRCA2 mutation did not appear to present a
more severe phenotype (52). We also identiﬁed three
families that included double heterozygotes with a causal
mutation in BRCA1 and a causal mutation in BRCA2.
Coexistence of causal mutations in BRCA1 and BRCA2
is unusual in non-Ashkenazi populations. Two of
these three families did not harbor the Ashkenazi
founder mutations (unpublished data) (52), but these
three families presented a breast cancer and other
cancers syndrome.
UVs classiﬁed by GGC
Most information used to determine the pathogenicity of
an UV is indirect, such as segregation data, loss of hetero-
zygosity, absence of the UV in an unaffected subject or
in silico prediction based on the conservation, position and
nature of amino acid change or the impact on the mRNA.
We used co-occurrence data and predictive algorithms
to classify three BRCA2 variants (Table 4). The French
consortium uses these data to classify UVs in the
UMD-BRCA1/BRCA2 databases. For example, like
Goldgar et al., we classiﬁed the BRCA2 c.6100C>T
(p.Arg2034Cys) variant as a neutral variant (53). In our
database, this c.6100C>T variant was associated with
eight distinct causal mutations strongly suggesting that it
is not causal. However, the status of the BRCA2
c.6100C>T variant differed between the algorithms:
SIFT score was 0.07, corresponding to borderline patho-
genicity (0.05). The UMD Predictor tool contained the
score SIFT but also other scores. The ﬁnal conclusion of
neutrality was based on a combination of prediction
programs with co-occurrence data. We discuss the contri-
bution of the 3D structure in Supplementary Data.
CONCLUSION
BRCA1 and BRCA2 are the two genes principally
involved in predisposition to breast and ovarian cancer.
Classiﬁcation of UVs of BRCA1 and BRCA2 has major
implications for hereditary forms of these malignancies.
Most variants identiﬁed to date cannot yet be deﬁnitively
classiﬁed as causal or neutral. The French UMD-BRCA1/
BRCA2 databases, which collect all variants (neutral,
causal and UVs), differ from other BRCA databases by
the fact that they contain co-occurrence data for all
variants, allowing the GGC consortium to classify a
number of UVs. In the future, co-occurrence data and
structural approaches should help to classify further un-
classiﬁed BRCA1/BRCA2 variants.
Table 4. Variants classiﬁed by GGC
BRCA2
Variant (cDNA level) c.6100C>T c.7008-62A>G c.9257-16T>C
Variant (protein level) p.Arg2034Cys – –
Reported in UMD-BRCA1/BRCA2 137 106 55
Co-occurrence with a causal mutation 16 (9) 6 8 (4)
dbSNP Rs1799954 – rs11571818
Align-GVGD GV=257.44, GD=11.33, C0 (less likely) ND ND
PolyPhen 0.423 (benign) ND ND
SIFT 0.07 (no deleterious) ND ND
UMD-Predictor 82 (pathogenic) ND ND
Literature data Polymorphism Neutral Neutral/Polymorphism
Classiﬁcation BIC database UV (97) UV (2) UV (6)
Classiﬁcation UMD-BRCA1/BRCA2 database Polymorphism Neutral Neutral
The enriched deleterious group consisted of those substitutions with Align-GVGD scores of GV<62 and GD>0 and SIFT scores  0.05. The
enriched neutral group consisted of those substitutions with Align-GVGD scores of GV>0 and GD <62 and SIFT scores >0.1. PolyPhen results
for each variant were classiﬁed as benign (score 0.5), possibly damaging (0.5< score< 2), probably damaging (score>2), and unknown. UMD
predictor results for each missense were classiﬁed as polymorphism (score 50), probable polymorphism (50 score 64), probably pathogenic
(65 score 74) and pathogenic (score>74). ND: not determined because algorithms only predict the impact of missense mutations.
Nucleic Acids Research, 2012,Vol.40, Database issue D999SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1 and 2, Supplementary Figures
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